---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-067012"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T10:41:32.327227+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx Q2 revenue falls 1% to $13.8M, GAAP EPS loss $(0.24), cuts 2023 outlook.

## Summary
- Revenue $13.8M, down 1% YoY; gross profit $7.8M, down 13%.
- GAAP net loss $(4.2)M ($(0.24)/share); non-GAAP net loss $(0.2)M ($(0.01)/share).
- Repurchased 526,999 shares at avg $14.27 for $7.5M in Q2.
- RWD.AI-enabled business saw 186% YoY growth in H1 2023.
- Full-year 2023 revenue guidance cut to mid-$50s to low-$60s million; gross margin 55-59%.

## SEC filing metadata
- accession: 0001213900-23-067012
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000121390023067012/0001213900-23-067012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000121390023067012/ea183450-8k_optimizerx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-067012
- JSON: https://secwatch.observer/filing/0001213900-23-067012.json
- Plain text: https://secwatch.observer/filing/0001213900-23-067012.txt

## Key facts
- Earnings Releases
  OptimizeRx Corp reported fiscal year 2023 results: revenue mid-50 to low-60 million dollars.
  - Period: fiscal year 2023
  - Revenue: mid-50 to low-60 million dollars
  - Result: guidance update
  source text: Based on first half results, the Company is updating its full year financial outlook for 2023. Revenues are now expected to be in the mid-50 to low-60 million dollar range with a gross margin rate between 55% and 59%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1448431/000121390023067012/0001213900-23-067012-index.htm
- Earnings Releases
  OptimizeRx Corp reported quarter ended June 30, 2023 results: net income $(4.2) million, EPS $(0.24).
  - Period: quarter ended June 30, 2023
  - Net income: $(4.2) million
  - EPS: $(0.24)
  - Result: reported results
  source text: Revenue in the second quarter of 2023 decreased 1% to $13.8 million, as compared to $14.0 million in the same year ago period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1448431/000121390023067012/0001213900-23-067012-index.htm
- Earnings Releases
  OptimizeRx Corp reported quarter ended June 30, 2023 results: net income $(4.2) million, EPS $(0.24).
  - Period: quarter ended June 30, 2023
  - Net income: $(4.2) million
  - EPS: $(0.24)
  - Result: reported results
  source text: GAAP net loss totaled $(4.2) million or $(0.24) per basic and diluted shares outstanding in the second quarter, as compared to $(3.9) million or $(0.21) during the second quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1448431/000121390023067012/0001213900-23-067012-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.